Cargando…

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication

OBJECTIVE: The aim of this study was to evaluate the changes in treatment satisfaction after switching to paliperidone extended-release (ER) in Chinese schizophrenia patients dissatisfied with their previous antipsychotic treatment. METHODS: In this 8-week, open-label, single-arm, multicenter, prosp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Fu De, Li, Juan, Tan, Yun Long, Liang, Wei Ye, Zhang, Rongzhen, Wang, Ning, Feng, Wei, Cai, Shangli, Zhuo, Jian Min, Zhang, Li Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402724/ https://www.ncbi.nlm.nih.gov/pubmed/28458549 http://dx.doi.org/10.2147/NDT.S130483

Ejemplares similares

Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study
por: Si, Tian Mei, et al.
Publicado: (2019)

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials
por: Cai, Shangli, et al.
Publicado: (2015)

The Influence of Previous Antipsychotic Polypharmacy Versus Monotherapy on the Effectiveness of Antipsychotic after Switching to Paliperidone Extended-release
por: Lee, Hee-Won, et al.
Publicado: (2013)

Influencing Factors and Predictors of Early Response in Schizophrenia Patients Receiving the Paliperidone Extended-Release Tablets (Paliperidone ER)
por: Jung, Seung-Ho, et al.
Publicado: (2013)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2008)

Effects of paliperidone extended release on the symptoms and functioning of schizophrenia
por: Huang, Min-Wei, et al.
Publicado: (2012)

Paliperidone extended-release: does it have a place in antipsychotic therapy?
por: Gahr, Maximilian, et al.
Publicado: (2011)

Benefit–risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia
por: Levitan, Bennett, et al.
Publicado: (2016)

The Dissatisfied Worker
por: Smith, Kinsley R.
Publicado: (1931)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
por: Zhao, Jingping, et al.
Publicado: (2017)

Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia
por: Spina, Edoardo, et al.
Publicado: (2011)

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
por: Jariyavilas, Apichat, et al.
Publicado: (2017)

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study
por: Geitona, Maria, et al.
Publicado: (2008)

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study
por: Geitona, Maria, et al.
Publicado: (2009)

Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence
por: Si, Tianmei, et al.
Publicado: (2018)

The anesthesiologist and the dissatisfied patient
por: Mendes, Florentino Fernandes
Publicado: (2021)

Who is dissatisfied with anesthesia?()
por: Simões, Claudia Marquez
Publicado: (2021)

The Dissatisfied Dental Colleges
Publicado: (1904)

Evaluation of sleep profile in schizophrenia patients treated with extended-release paliperidone: an open-label prospective study in Southeast Asia
por: Kongsakon, Ronnachai, et al.
Publicado: (2017)

The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
por: Nakagawa, Ryoko, et al.
Publicado: (2015)

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Sexual life satisfaction of methadone-maintained Chinese patients: individuals with pain are dissatisfied with their sex lives
por: Zhong, Bao-Liang, et al.
Publicado: (2018)

Tablets of paliperidone using compression-coated technology for controlled ascending release
por: Tang, Yingying, et al.
Publicado: (2018)

Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics
por: Schreiner, A, et al.
Publicado: (2015)

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
por: Li, Nan, et al.
Publicado: (2018)

Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics
por: Kwon, Jun Soo, et al.
Publicado: (2015)

Treatment of bipolar mania with paliperidone extended-release
por: Kotorki, Paraskevi, et al.
Publicado: (2010)

Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophrenia
por: Helldin, Lars, et al.
Publicado: (2015)

An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
por: Si, TianMei, et al.
Publicado: (2015)

Paliperidone Extended-Release Tablets for the Treatment of Methamphetamine Use Disorder in Chinese Patients After Acute Treatment: A Randomized, Double-Blind, Placebo-Controlled Exploratory Study
por: Wang, Gang, et al.
Publicado: (2019)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
por: Zhang, Hongyan, et al.
Publicado: (2016)

T211. COMPARISON OF REHOSPITALIZATION RATE IN INDIVIDUALS WITH SCHIZOPHRENIA CHANGED FROM PALIPERIDONE PALMITATE TO ORAL ANTIPSYCHOTICS
por: Ju Lee, Bong, et al.
Publicado: (2020)

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
por: Shi, Chuan, et al.
Publicado: (2016)

Role of paliperidone extended-release in treatment of schizoaffective disorder
por: Canuso, Carla M, et al.
Publicado: (2010)

The role of paliperidone extended release for the treatment of bipolar disorder
por: Marino, Jehan, et al.
Publicado: (2012)

Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
por: Druais, Sylvain, et al.
Publicado: (2016)

Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
por: Pesa, Jacqueline A., et al.
Publicado: (2015)

Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia
por: Brown, Brianne, et al.
Publicado: (2019)

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
por: Si, Tianmei, et al.
Publicado: (2015)

Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study()
por: Pandina, Gahan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_geccdob7n32bustmgd2e3mcigb